328 related articles for article (PubMed ID: 30371946)
21. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.
Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM
J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924
[TBL] [Abstract][Full Text] [Related]
22. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
Tkachuk S; Collins K; Ensom MHH
Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
[TBL] [Abstract][Full Text] [Related]
24. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
Epps QJ; Epps KL; Young DC; Zobell JT
Pediatr Pulmonol; 2020 Jan; 55(1):33-57. PubMed ID: 31609097
[TBL] [Abstract][Full Text] [Related]
25. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
[TBL] [Abstract][Full Text] [Related]
27. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
Fung L
Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Vancomycin Dose for Recommended Trough Concentrations in Pediatric Patients With Cystic Fibrosis.
Amin RW; Guttmann RP; Harris QR; Thomas JW
J Clin Pharmacol; 2018 May; 58(5):662-665. PubMed ID: 29319843
[TBL] [Abstract][Full Text] [Related]
29. Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.
Waterer G; Lord J; Hofmann T; Jouhikainen T
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31964790
[TBL] [Abstract][Full Text] [Related]
30. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population.
Kishk OA; Lardieri AB; Heil EL; Morgan JA
J Pediatr Pharmacol Ther; 2017; 22(1):41-47. PubMed ID: 28337080
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis.
Le J; Bradley JS; Hingtgen S; Skochko S; Black N; Jones RN; Lim M; Capparelli EV
Pediatr Pulmonol; 2017 Nov; 52(11):1424-1434. PubMed ID: 28910514
[TBL] [Abstract][Full Text] [Related]
33. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
Patel K; Crumby AS; Maples HD
Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
[TBL] [Abstract][Full Text] [Related]
34. The relationship of vancomycin 24-hour AUC and trough concentration.
Nix DE; Davis LE; Matthias KR
Am J Health Syst Pharm; 2022 Mar; 79(7):534-539. PubMed ID: 34849533
[TBL] [Abstract][Full Text] [Related]
35. Clinical validation of the two-point method for predicting vancomycin AUC based on peak and trough plasma concentrations.
Wang L; Lin X; Wang L; Ye H; Lin Y; Ruan J; Shi S
Int J Clin Pharm; 2022 Dec; 44(6):1325-1331. PubMed ID: 36136207
[TBL] [Abstract][Full Text] [Related]
36. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
37. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
[TBL] [Abstract][Full Text] [Related]
38. Establishment of an AUC
Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
[TBL] [Abstract][Full Text] [Related]
39. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the mathematical equation and trapezoidal approach for 24 h area under the plasma concentration-time curve calculation in patients who received intravenous vancomycin in an acute care setting.
Chanapiwat P; Paiboonvong T; Rattanaumpawan P; Montakantikul P
Pharmacol Res Perspect; 2023 Feb; 11(1):e01046. PubMed ID: 36588162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
